- MD, Sao Paulo State University
About Paulo Fontes
Dr. Paulo Fontes is a transplant surgeon, a scientist, an entrepreneur and the medical/scientific director of an investment fund. He is Professor of Surgery, Director, Research & Innovation, Department of Surgery, WVU Medicine, West Virginia University. He is a co-founder and share holder of 2 startup companies: 1) Virtech Bio Inc., Natick, MA (Chairman of the Scientific Advisory Board) and 2) LyGenesis, Pittsburgh, PA (Chief Medical Officer). Dr. Fontes is also the Director of VGS Foundation, Sao Paulo, Brazil, which is a non-profit life science foundation linked to a $65M fund. He was a faculty member at the University of Pittsburgh for 27 years as a member of the Starzl Transplantation Institute, Department of Surgery, UPMC and also a Deputy Director, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh.
Dr. Fontes received his MD degree from Sao Paulo State University (UNESP) in 1985 under a full scholarship program. He achieved board certification in General Surgery by the Brazilian College of Surgeons in 1989 and received further accreditation by the International College of Surgeons in 1990. He attended three additional post-doctoral training programs after completing his residence in general surgery: (1) Operative Technique & Experimental Surgery (Sao Paulo Federal University -UNIFESP, Department of Surgery, Sao Paulo, SP, Brazil 1990-1991); (2) Cell Transplantation & Transplant Immunology (STI, UPMC, Pittsburgh, PA, USA 1991-1993); and (3) Multi Organ Transplantation (STI, UPMC, Pittsburgh PA, USA, 1996-1998). He has been fully certified in transplant surgery by the American Society of Transplant Surgeons in 1998 and proudly accepted as a Fellow of the American College of Surgeons (FACS) in 2001.
Dr. Fontes received formal business education in three additional programs: (1) Mini-MBA program sponsored by the UPMC-Physician Service Division and the Katz Business School, University of Pittsburgh, 2007; (2) Kellogg School of Management, Northwestern University, Evanston, IL 2009; and (3) Joseph Katz Graduate School of Business, Office of Technology Management, University of Pittsburgh, 2012, in the Business of Commercial Innovation. He did additional training in analytics with the Department of Biomedical Informatics, U Pitt in 2016.
Dr. Fontes was the Director of the Liver Transplant Program at the STI, UPMC, for almost a decade while performing and assisting in over 1,500 liver transplant procedures and managing over 10,000 patients. He was also a Co-Founder and the first Medical Director of the Organ Referral Center, UPMC. Dr. Fontes has contributed to an all-time UPMC record of 850 transplant procedures (all organs combined) in 2007. He received the UPMC’s Award for Commitment and Excellence in Service (ACES) in 2010, acknowledging his unlimited devotion to patient care and for the institution’s mission and values. He has received over 30 awards and honors, including a nomination into the “America’s Best Physicians” 2016 and 2017 Editions, National Consumer Advisory Board, “America’s Best in Medicine” 2017, Hauppauge NY, the TechConnect Innovation Award 2016, 2 University of Pittsburgh Innovation Awards (2016, 2017), UPMC’s 2016 Excellence in Patient Experience Award and the Coulter Award in 2017.
Dr. Fontes has contributed to over 250 publications (115 peer-review papers, 10 book chapters, and 126 published abstracts). He has been directly involved in the training of more than 90 transplant surgeons since 1998 and continued to teach and mentor medical students. Dr. Fontes has given over 120 national and international lectures. He is a member of the Editorial Review Board of 24 scientific journals and grant agencies. He has received financial support for his ongoing research from 7 different funding agencies, including the Department of Defense (DOD), the SBIR and the NIH.
Dr. Fontes is the inventor of 3 patents licensed by VirTech Bio Inc. He started the Machine Perfusion (MP) Program at the STI, UPMC, in 2011 by creating a new line of investigation at the MIRM through a $1M charitable grant. He led a comprehensive multidisciplinary group who developed new technologies in organ and tissue preservation by developing new MP devices in combination with new hemoglobin-based oxygen carrier (HBOC) solutions. Their liver technology is currently under FDA evaluation for the inception of their first US clinical trial for liver preservation. The liver preservation technology has been validated by 2 European groups and it’s about to start a clinical trial in the Netherlands.
Dr. Fontes has developed new analytical approaches for monitoring organs and tissues during ex-vivo perfusion. In collaboration with Dr. Yoram Vodovotz, they have combined transcriptomics, inflammatory markers and metabolomics data by using computational biology tools as a way to compare ischemia-reperfusion (IR) pathways during liver preservation. The group has also elucidated potential metabolic pathways related to liver hibernation during MP under subnormothermic conditions in their swine model.
Dr. Fontes has performed additional experiments on hepatic mitochondrial functionality and anatomical features during MP and liver reperfusion in collaboration with Drs. Sruti Shiva and Dona Stolz.
Dr. Fontes has expanded the applications of this new ex-vivo technology towards vascularized composite allotransplants and has received 3 additional awards from the DOD while developing a new MP medical device for limb preservation in collaboration with Arjan van der Plaats, PhD, Organ Assist, Groningen, Netherlands. In collaboration with William R. Light, PhD, CSO, Virtech Bio Inc., they have received a SBIR phase 1 award to develop a new human-derived HBOC for ex-vivo applications.
Dr. Fontes is an experienced cell transplant surgeon. He was involved in the initial STI, UPMC clinical trial for islet transplants in the 90s where 26 patients were transplanted. He also performed over 350 bone marrow transplants in a NIH-sponsored clinical trial aimed to induce donor-specific tolerance at the STI, UPMC. He created a new large animal model for hepatocyte transplants and started LyGenesis in collaboration with Eric Lagasse, PhD and CSO and Michael Hufford, PhD and CEO. They have received a $3M series fund from Juvenescence, Isle of Man and they are currently completing their pre-clinical experiments for their IND application with the FDA. They intend to run their first clinical trial with this with this revolutionary technology that develops ectopic livers within the lymph nodes at the WVU.
View a list of Dr. Fontes’ publications here [http://www.ncbi.nlm.nih.gov/pubmed?term=(%22university%20of%20pittsburgh%22)%20AND%20%22fontes%2C%20paulo%22].
U Pitt/ McGowan from last year.
Patient Care Information
Fellowship, Multi organ transplantation
University of Pittsburgh
Fellowship, Cell Transplantation and Transplant Immunolgy
University of Pittsburgh